Stabilis

Zidovudine



Noms commerciaux

Retrovir	Allemagne, Belgique, Canada, Chili, Colombie, Equateur, Etats Unis d'Amérique, Grande Bretagne, Grèce, Irlande, Italie, Luxembourg, Malaisie, Mexique, Nouvelle Zélande, Pays bas, Pérou, Pologne, Portugal, Suède, Suisse, Turquie, Vénézuela
Zidovudina	Argentine, Espagne

Stabilité des solutions

PVC		4 mg/ml	25°C	?	8			338
PVC		4 mg/ml	4°C		8			338

Stabilité en mélange

PVC		2 mg/ml	23°C		Dobutamine hydrochloride : 1 mg/ml	24	1878
PVC		2 mg/ml	23°C		Ranitidine hydrochloride : 0,5 mg/ml	24	1900
PVC		2 mg/ml	4°C		Ranitidine hydrochloride : 0,5 mg/ml	24	1900
PVC		2 mg/ml	4°C	?	Dobutamine hydrochloride : 1 mg/ml	24	1878

Compatibilités

		Zidovudine : 4 mg/ml		301
		Zidovudine : 4 mg/ml Allopurinol sodium : 3 mg/ml		307
		Zidovudine : 10 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Zidovudine : 4 mg/ml		316
		Zidovudine : 4 mg/ml		1415
		Zidovudine : 4 mg/ml Aciclovir sodium : 7 mg/ml		337
		Zidovudine : 4 mg/ml Amifostine : 10 mg/ml		3
		Zidovudine : 4 mg/ml Amikacin sulfate : 4 mg/ml		337
		Zidovudine : 4 mg/ml Amphotericin B : 0.6 mg/ml		337
		Zidovudine : 4 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml		921
		Zidovudine : 4 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Zidovudine : 4 mg/ml Aztreonam : 40 mg/ml		337
		Zidovudine : 4 mg/ml Aztreonam : 40 mg/ml		99
		Zidovudine : 4 mg/ml Ceftazidime : 20 mg/ml		337
		Zidovudine : 4 mg/ml Ceftriaxone disodium : 20 mg/ml		337
		Zidovudine : 4 mg/ml Cimetidine hydrochloride : 6 mg/ml		337
		Zidovudine : 4 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Zidovudine : 4 mg/ml Clindamycin phosphate : 12 mg/ml		337

	✓	Zidovudine : 4 mg/ml Co-trimoxazole : 0.53/2.6 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Dexamethasone sodium phosphate : 0.16 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Dobutamine hydrochloride : 5 mg/ml	◆	337
	✓	Zidovudine : 2 mg/ml Dobutamine hydrochloride : 1 mg/ml	▲	1878
	✓	Zidovudine : 4 mg/ml Docetaxel : 0.9 mg/ml	◆	1754
	✓	Zidovudine : 4 mg/ml Dopamine hydrochloride : 1.6 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Doripenem : 5 mg/ml	▲◆	2262
	✓	Zidovudine : 4 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml	◆	251
	✓	Zidovudine : 4 mg/ml Erythromycin lactobionate : 20 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Etoposide phosphate : 5 mg/ml	◆	1410
	✓	Zidovudine : 4 mg/ml Filgrastim : 30 µg/ml	◆	244
	✓	Zidovudine : 10 mg/ml Fluconazole : 2 mg/ml	▲	496
	✓	Zidovudine : 4 mg/ml Fludarabine phosphate : 1 mg/ml	◆	492
	✓	Zidovudine : 4 mg/ml Gemcitabine hydrochloride : 10 mg/ml	▲	1423
	✓	Zidovudine : 4 mg/ml Gentamicin sulfate : 2 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Granisetron hydrochloride : 0.05 mg/ml	◆	182
	✓	Zidovudine : 4 mg/ml Heparin sodium : 100 UI/ml	◆	337
	✓	Zidovudine : 4 mg/ml Imipenem - cilastatin sodium : 5 mg/ml	◆	337
↓	✗	Zidovudine : 4 mg/ml Lansoprazole : 0.55 mg/ml	▲	1625
	✓	Zidovudine : 4 mg/ml Linezolid : 2 mg/ml	∅	1925
	✓	Zidovudine : 4 mg/ml Lorazepam : 0.08 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Melphalan : 0.1 mg/ml	▲	169
	✓	Zidovudine : 4 mg/ml Meropenem : 1 mg/ml	▲	266
4	✗	Zidovudine : 4 mg/ml Meropenem : 20 & 50 mg/ml	▲	266
	✓	Zidovudine : 4 mg/ml Metoclopramide hydrochloride : 2 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Morphine sulfate : 1 mg/ml	◆	337

	✓	Zidovudine : 4 mg/ml Nafcillin sodium : 20 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Ondansetron hydrochloride : 1 mg/ml	▲	334
	✓	Zidovudine : 4 mg/ml Oxacillin sodium : 20 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Oxytocin : 0,02 UI/ml	◆	1725
	✓	Zidovudine : 2 & 4 mg/ml Oxytocin : 0,01 UI/ml	◆	1926
	✓	Zidovudine : 4 mg/ml Oxytocin : 0,02 UI/ml	▲	1725
	✓	Zidovudine : 4 mg/ml Paclitaxel : 1.2 mg/ml	◆	248
	✓	Zidovudine Pantoprazole sodium		2090
	✓	Zidovudine : 10 mg/ml Paracetamol : 10 mg/ml		4742
	✓	Zidovudine : 4 mg/ml Pemetrexed disodium : 20 mg/ml	▲	1953
	✓	Zidovudine : 4 mg/ml Penicillin G sodium : 0,05 MUI/ml	▲	1725
	✓	Zidovudine : 4 mg/ml Penicillin G sodium : 0,025 MUI/ml	▲	1725
	✓	Zidovudine : 4 mg/ml Penicillin G sodium : 0,025 MUI/ml	◆	1725
	✓	Zidovudine : 4 mg/ml Penicillin G sodium : 0,05 MUI/ml	◆	1725
	✓	Zidovudine : 4 mg/ml Pentamidine isetionate : 6 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Phenylephrine hydrochloride : 1 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Piperacillin sodium : 4 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml	◆	81
	✓	Zidovudine : 4 mg/ml Potassium chloride : 670 mEq/l	◆	337
	✓	Zidovudine : 4 mg/ml Ranitidine hydrochloride : 1 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml	▲	59
	✓	Zidovudine : 4 mg/ml Sargramostim : 10 µg/ml	▲	335
	✓	Zidovudine : 4 mg/ml Teniposide : 0.1 mg/ml	◆	905
	✓	Zidovudine : 4 mg/ml Thiotepa : 1 mg/ml	◆	249
	✓	Zidovudine : 4 mg/ml Tobramycin sulfate : 2 mg/ml	◆	337
	✓	Zidovudine : 4 mg/ml Vancomycin hydrochloride : 15 mg/ml	▲	337

		Zidovudine : 4 mg/ml Vinorelbine tartrate : 1 mg/ml		84

Voie d'administration

Bibliographie

	Type	Source
3	Revue	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Revue	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
81	Revue	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Revue	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Revue	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Revue	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Revue	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
248	Revue	Trissel LA, Martinez JF. Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection. Am J Hosp Pharm 1993 ; 50: 300-304.
249	Revue	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	Revue	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
266	Revue	Patel PR. Compatibility of meropenem with commonly used injectable drugs. Am J Health-Syst Pharm 1996 ; 53: 2853-2855.

299	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
301	Revue	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Revue	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
316	Revue	Veltri M, Lee CKK. Compatibility of neonatal parenteral nutrient solutions with selected intravenous drugs. Am J Health-Syst Pharm 1996 ; 53: 2611-2613.
334	Revue	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Revue	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
337	Revue	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
338	Revue	Lam NP, Kennedy PE, Jarosinski PF, Galleli JF. Stability of zidovudine in 5% dextrose injection and 0.9% sodium chloride injection. Am J Hosp Pharm 1991 ; 48: 280-282.
492	Revue	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Revue	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
905	Revue	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
921	Revue	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1410	Revue	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Revue	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Revue	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1625	Revue	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.

1725	Revue	Oliver C, Law S. Compatibility of oxytocin, zidovudine, and penicillin G. Can J Hosp Pharm 2001 ; 54: 112-113.
1754	Revue	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1878	Revue	Musami P, Stewart JT, Will Taylor E. Stability of zidovudine and dobutamine hydrochloride injections in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23±2°C) and 4°C in 50 ml polyvinyl chloride bags up to 24 hours. Int J Pharm Compound 2004 ; 8, 1: 73-76.
1900	Revue	Musami P, Stewart JT, Taylor EW. Stability of zidovudine and ranitidine in 0.9% sodium chloride and 5% dextrose injections stored at ambient temperature (23°C±2°C) and 4°C in 50 ml polyvinylchloride bags up to 24 hours. Int J Pharm Compound 2004 ; 8, 3: 236-239.
1925	Revue	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1926	Revue	Anderson PL, Miller S, Bushman LR. Stability of zidovudine with oxytocin in a simulated Y-site injection. Am J Health-Syst Pharm 2004 ; 61: 394-396.
1953	Revue	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1982	Revue	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2090	Revue	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2262	Revue	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administratioN Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
3824	Revue	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
4742	Revue	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.

Stabilis

Zidovudine



Stabilité des préparations

		100 mg Retrovir®	Sirop simple >> 10 mL	21-25°C		90			3798

Facteur influençant la stabilité

					3798

Bibliographie

	Type	Source
3798	Revue	Radwan M.A. Stability indicating HPLC assay of zidovudine in extemporaneously syrup. Analytical Letter 1994 . 27: 1159-1164.

Dictionnaire

	Antiviral		Injectable
	Noms commerciaux		Stabilité des solutions
	Contenant		Molécule
	Concentration		Température
	Conservation		Durée de stabilité
	Biosimilaire		Données conflictuelles
	Bibliographie		Polyvinyl chlorure
	NaCl 0,9% ou glucose 5%		Non précisée
	Jour		A l'abri de la lumière
	Stabilité en mélange		Solvant
	Molécule		Lumière
	Heure		Compatibilités
	Compatible		Nutrition parentérale (mélange binaire)
	Chlorure de sodium 0,9%		Nutrition parentérale (mélange ternaire)
	Glucose 5%		Précipitation immédiate
	Incompatible		Aucun
	Changement de couleur à 4 heures		Voie d'administration
	Perfusion intraveineuse		Bibliographie
	Solution buvable		Stabilité des préparations
	Origine		Excipient
	Verre		Gélules
	Facteur influençant la stabilité		Provoque
	Dégradation		Dictionnaire